Nuvation Bio Inc - Ordinary Shares - Class A
NUVB
Market Cap$841.37M
Close$
$0.29
88.3% downside
Current Fair Value
88.3% downsideOvervalued by 88.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $841.37 Million |
|---|---|
| Enterprise Value | $815.35 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.11 |
| Beta | 1.37 |
| Outstanding Shares | 338,612,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.38 |
|---|---|
| PEG | -0.53 |
| Price to Sales | - |
| Price to Book Ratio | 2.48 |
| Enterprise Value to Revenue | 74.41 |
| Enterprise Value to EBIT | -4.04 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Nuvation Bio Inc
36 employeesNuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically ...